| Stem definition | Drug id | CAS RN |
|---|---|---|
| phosphatidylinositol 3-kinase inhibitors, antineoplastics | 5441 | 1532533-67-7 |
None
None
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | 4.483 | High | 1 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 1.045 | High | 1 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 21.577 | 10^-6 cm/s | High | 1 |
| dh-clint | Dog hepatocyte intrinsic clearance | 9.528 | uL/min/10^6 cells | High | 1 |
| dppb | Dog plasma protein binding (% unbound) | 0.590 | % | High | 1 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 2.370 | % | High | 1 |
| herg | hERG pIC50 | 4.955 | pIC50 | High | 1 |
| hh-clint | Human hepatocyte intrinsic clearance | 7.047 | uL/min/10^6 cells | High | 1 |
| hlm-clint | Human liver microsomal intrinsic clearance | 10.447 | uL/min/mg protein | High | 1 |
| hppb | Human plasma protein binding (% unbound) | 0.460 | % | High | 1 |
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 0.354 | High | 1 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 31.550 | High | 1 | |
| mppb | Mouse plasma protein binding (% unbound) | 0.540 | High | 1 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 1.507 | High | 1 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pppb | Pig plasma protein binding (% unbound) | 1.050 | % | High | 1 |
| rh-clint | Rat hepatocyte intrinsic clearance | 37.497 | uL/min/10^6 cells | High | 1 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 4.280 | % | High | 1 |
| rppb | Rat plasma protein binding (% unbound) | 0.590 | % | High | 1 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 2.786 | uM | High | 1 |
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Feb. 5, 2021 | FDA | TG THERAPEUTICS Inc |
None
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Nervous system disorder | 57.90 | 50.49 | 13 | 132 | 17182 | 42604008 |
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Nervous system disorder | 60.01 | 57.07 | 13 | 159 | 31708 | 110557419 |
None
| Source | Code | Description |
|---|---|---|
| ATC | L01EX25 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS PROTEIN KINASE INHIBITORS Other protein kinase inhibitors |
| MeSH PA | D000081082 | Phosphoinositide-3 Kinase Inhibitors |
| MeSH PA | D004791 | Enzyme Inhibitors |
| FDA MoA | N0000175082 | Kinase Inhibitors |
| FDA EPC | N0000175605 | Kinase Inhibitor |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:233423 | antifibrotic agent |
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Relapsed or refractory follicular lymphoma | indication | 55150002 | |
| Relapsed or refractory marginal zone lymphoma | indication | 447100004 |
None
None
None
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| EQ 200MG BASE | UKONIQ | TG THERAPS | N213176 | Feb. 5, 2021 | DISCN | TABLET | ORAL | 10072013 | July 2, 2033 | RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (FL) WHO HAVE RECEIVED AT LEAST THREE PRIOR LINES OF SYSTEMIC THERAPY |
| EQ 200MG BASE | UKONIQ | TG THERAPS | N213176 | Feb. 5, 2021 | DISCN | TABLET | ORAL | 10072013 | July 2, 2033 | RELAPSED OR REFRACTORY MARGINAL ZONE LYMPHOMA (MZL) WHO HAVE RECEIVED AT LEAST ONE PRIOR ANTI-CD20-BASED REGIMEN |
| EQ 200MG BASE | UKONIQ | TG THERAPS | N213176 | Feb. 5, 2021 | DISCN | TABLET | ORAL | 10570142 | July 2, 2033 | RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (FL) WHO HAVE RECEIVED AT LEAST THREE PRIOR LINES OF SYSTEMIC THERAPY |
| EQ 200MG BASE | UKONIQ | TG THERAPS | N213176 | Feb. 5, 2021 | DISCN | TABLET | ORAL | 10570142 | July 2, 2033 | RELAPSED OR REFRACTORY MARGINAL ZONE LYMPHOMA (MZL) WHO HAVE RECEIVED AT LEAST ONE PRIOR ANTI-CD20-BASED REGIMEN |
| EQ 200MG BASE | UKONIQ | TG THERAPS | N213176 | Feb. 5, 2021 | DISCN | TABLET | ORAL | 10981919 | July 2, 2033 | RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (FL) WHO HAVE RECEIVED AT LEAST THREE PRIOR LINES OF SYSTEMIC THERAPY |
| EQ 200MG BASE | UKONIQ | TG THERAPS | N213176 | Feb. 5, 2021 | DISCN | TABLET | ORAL | 10981919 | July 2, 2033 | RELAPSED OR REFRACTORY MARGINAL ZONE LYMPHOMA (MZL) WHO HAVE RECEIVED AT LEAST ONE PRIOR ANTI-CD20-BASED REGIMEN |
| EQ 200MG BASE | UKONIQ | TG THERAPS | N213176 | Feb. 5, 2021 | DISCN | TABLET | ORAL | 9669033 | July 2, 2033 | RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (FL) WHO HAVE RECEIVED AT LEAST THREE PRIOR LINES OF SYSTEMIC THERAPY |
| EQ 200MG BASE | UKONIQ | TG THERAPS | N213176 | Feb. 5, 2021 | DISCN | TABLET | ORAL | 9669033 | July 2, 2033 | RELAPSED OR REFRACTORY MARGINAL ZONE LYMPHOMA (MZL) WHO HAVE RECEIVED AT LEAST ONE PRIOR ANTI-CD20-BASED REGIMEN |
| EQ 200MG BASE | UKONIQ | TG THERAPS | N213176 | Feb. 5, 2021 | DISCN | TABLET | ORAL | 10414773 | May 26, 2035 | RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (FL) WHO HAVE RECEIVED AT LEAST THREE PRIOR LINES OF SYSTEMIC THERAPY |
| EQ 200MG BASE | UKONIQ | TG THERAPS | N213176 | Feb. 5, 2021 | DISCN | TABLET | ORAL | 10414773 | May 26, 2035 | RELAPSED OR REFRACTORY MARGINAL ZONE LYMPHOMA (MZL) WHO HAVE RECEIVED AT LEAST ONE PRIOR ANTI-CD20-BASED REGIMEN |
| EQ 200MG BASE | UKONIQ | TG THERAPS | N213176 | Feb. 5, 2021 | DISCN | TABLET | ORAL | 10947244 | May 26, 2035 | RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (FL) WHO HAVE RECEIVED AT LEAST THREE PRIOR LINES OF SYSTEMIC THERAPY |
| EQ 200MG BASE | UKONIQ | TG THERAPS | N213176 | Feb. 5, 2021 | DISCN | TABLET | ORAL | 10947244 | May 26, 2035 | RELAPSED OR REFRACTORY MARGINAL ZONE LYMPHOMA (MZL) WHO HAVE RECEIVED AT LEAST ONE PRIOR ANTI-CD20-BASED REGIMEN |
| EQ 200MG BASE | UKONIQ | TG THERAPS | N213176 | Feb. 5, 2021 | DISCN | TABLET | ORAL | 9969740 | May 26, 2035 | RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (FL) WHO HAVE RECEIVED AT LEAST THREE PRIOR LINES OF SYSTEMIC THERAPY |
| EQ 200MG BASE | UKONIQ | TG THERAPS | N213176 | Feb. 5, 2021 | DISCN | TABLET | ORAL | 9969740 | May 26, 2035 | RELAPSED OR REFRACTORY MARGINAL ZONE LYMPHOMA (MZL) WHO HAVE RECEIVED AT LEAST ONE PRIOR ANTI-CD20-BASED REGIMEN |
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| EQ 200MG BASE | UKONIQ | TG THERAPS | N213176 | Feb. 5, 2021 | DISCN | TABLET | ORAL | Feb. 5, 2026 | NEW CHEMICAL ENTITY |
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform | Kinase | INHIBITOR | Kd | 8.21 | SCIENTIFIC LITERATURE | DRUG LABEL | |||
| Casein kinase I isoform epsilon | Kinase | INHIBITOR | Kd | 6.74 | SCIENTIFIC LITERATURE | DRUG LABEL | |||
| Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform | Kinase | INHIBITOR | Kd | 5 | SCIENTIFIC LITERATURE | ||||
| Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | Kinase | INHIBITOR | Kd | 5 | SCIENTIFIC LITERATURE | ||||
| Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform | Kinase | INHIBITOR | Kd | 5.85 | SCIENTIFIC LITERATURE |
| ID | Source |
|---|---|
| D11322 | KEGG_DRUG |
| 38073MQB2A | UNII |
| 1532533-72-4 | SECONDARY_CAS_RN |
| C4682392 | UMLSCUI |
| CHEBI:756005 | CHEBI |
| CHEMBL3948730 | ChEMBL_ID |
| 72950888 | PUBCHEM_CID |
| DB14989 | DRUGBANK_ID |
| CHEMBL3989869 | ChEMBL_ID |
| 10350 | INN_ID |
| C000626319 | MESH_SUPPLEMENTAL_RECORD_UI |
| 8916 | IUPHAR_LIGAND_ID |
| 1148656009 | SNOMEDCT_US |
| 1148709002 | SNOMEDCT_US |
| 1148712004 | SNOMEDCT_US |
| 4040064 | VANDF |
| 343527 | MMSL |
| 39321 | MMSL |
| d09711 | MMSL |
| 018630 | NDDF |
| 018631 | NDDF |
| 2478438 | RXNORM |
| 38073MQB2A | INXIGHT DRUGS |
None